These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9671144)

  • 1. The combination of interleukin-2 and interferon alpha effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29.
    Bungard S; Flieger D; Schweitzer S; Sauerbruch T; Spengler U
    Cancer Immunol Immunother; 1998 Jun; 46(4):213-20. PubMed ID: 9671144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.
    Ottonello L; Morone P; Dapino P; Dallegri F
    Blood; 1996 Jun; 87(12):5171-8. PubMed ID: 8652830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
    Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
    Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12.
    Flieger D; Spengler U; Beier I; Kleinschmidt R; Sauerbruch T; Schmidt-Wolf IG
    J Immunother; 2000; 23(4):480-6. PubMed ID: 10916758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
    Flieger D; Spengler U; Beier I; Kleinschmidt R; Hoff A; Varvenne M; Sauerbruch T; Schmidt-Wolf I
    Hybridoma; 1999 Feb; 18(1):63-8. PubMed ID: 10211790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
    Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Liljefors M; Nilsson B; Mellstedt H; Frödin JE
    Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
    Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
    Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
    Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
    Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
    Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
    Caron PC; Lai LT; Scheinberg DA
    Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
    Flieger D; Hoff AS; Sauerbruch T; Schmidt-Wolf IG
    Clin Exp Immunol; 2001 Jan; 123(1):9-14. PubMed ID: 11167991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
    Pendurthi TK; Parker R; Schlom J; Primus FJ
    Int J Cancer; 1990 Dec; 46(6):1021-8. PubMed ID: 2123477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
    Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
    Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
    Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.